Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
Trial ID or NCT#
NCT00233415
Status
NOT RECRUITING
Purpose
The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy with radiosurgery for locally advanced pancreas cancer.
Official Title
Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer
Eligibility Criteria
Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Pancreatic tumors not to exceed 7.5 cm.
- * Histologically confirmed malignancies of the pancreas, (ampulla of Vater or periampullary duodenum, tumors may be included when the head of pancreas is secondarily involved and unresectable criteria are met).* Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy. CT criteria for unresectability include encasement of the superior mesenteric vein (SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery (SMA).* Patients with metastatic disease may be treated if they are symptomatic from the primary tumor.* Eastern Clinical Oncology Group performance status 0, 1 or 2.
Exclusion Criteria:
- Chemotherapy within 1 month of registration.
Investigator(s)
Quynh-Thu Le, MD
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Iris C. Gibbs, MD, FACR, FASTRO
Radiation oncologist,
Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Jeffrey Norton, MD
George A. Fisher Jr.
Medical oncologist,
Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Contact us to find out if this trial is right for you.
Contact
Stanford Cancer Clinical Trials Office
6504987061
View on ClinicalTrials.gov
